TScan Therapeutics's total assets for Q1 2026 were $201.99M, a decrease of -11.71% from the previous quarter. TCRX total liabilities were $105.07M for the fiscal quarter, a -0.56% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.